Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Clinical trial NCT02101268 · COMPLETED

Trial details

NCT number: NCT02101268
Sponsor: Sierra Oncology LLC - a GSK company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Start date: 2014-06-19
Primary completion: 2016-07-28
Enrollment: 156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.